Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2013

01-01-2013 | Epidemiology

Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case–control study

Authors: K. Bilinski, J. Boyages

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Login to get access

Abstract

The objective of this study is to examine the association between vitamin D status and risk of breast cancer in an Australian population of women. The study design is observational case–control study, performed at Westmead Breast Cancer Institute, Westmead Hospital, Sydney, Australia. 214 women newly diagnosed with breast cancer were matched to 852 controls, and their blood samples were tested at the same laboratory between August 2008 and July 2010. Circulating 25-hydroxyvitamin D (25(OH)D) concentration, was defined as sufficient (≥75 nmol/L), insufficient (50–74 nmol/L), deficient (25–49 nmol/L) or severely deficient (<25 nmol/L). The difference in median 25(OH)D concentration between cases and controls was reported, and the Mann–Whitney U test was used to determine the significance of the difference. Odds ratios and 95 % confidence intervals for the risk of breast cancer were estimated by Cox regression. Median plasma 25(OH)D was significantly lower in cases versus controls overall (53.0 vs 62.0 nmol/L, P < 0.001) and during summer (53.0 vs 68.0 nmol/L, P < 0.001) and winter (54.5 vs 63.0 nmol/L, P < 0.001). Median 25(OH)D was also lower in cases when stratified by BMI (<30, ≥30) and age group (<50, ≥50 years) compared to matched controls, although the difference failed to reach statistical significance. In a Cox regression model, plasma 25(OH)D was inversely associated with the odds ratio of breast cancer. Compared to subjects with sufficient 25(OH)D concentration, the odds ratios of breast cancer were 2.3 (95 % CI 1.3–4.3), 2.5 (95 % CI 1.6–3.9) and 2.5 (95 % CI 1.6–3.8) for subjects categorised as severely deficient, deficient or insufficient vitamin D status, respectively. The results of this observational case–control study indicate that a 25(OH)D concentration below 75 nmol/L at diagnosis was associated with a significantly higher risk of breast cancer. These results support previous research which has shown that lower 25(OH)D concentrations are associated with increased risk of breast cancer.
Literature
1.
2.
Zerwekh JE (2008) Blood biomarkers of vitamin D status. Am J Clin Nutr 87(4):1087S–11091PubMed
3.
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Nutrition Board IoM (1997) Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. National Academy of Sciences, Washington
4.
5.
Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC (2008) Relationship between low ultraviolet B irradiance and higher breast cancer risk in 107 countries. Breast J 14(3):255–260PubMedCrossRef
6.
Gorham ED, Garland FC, Garland CF (1990) Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 19(4):820–824PubMedCrossRef
7.
Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L (2009) Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 18(10):2655–2660. doi:10.​1158/​1055-9965.​EPI-09-0531 PubMedCrossRef
8.
Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14(8):1991–1997PubMedCrossRef
9.
Eliassen AH, Spiegelman D, Hollis B, Horst R, Willett W, Hankinson S (2011) Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res 13(3):R50PubMedCrossRef
10.
Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG (2008) Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 17(4):889–894PubMedCrossRef
11.
McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE (2009) Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast cancer research 11(4):R64. doi:10.​1186/​bcr2356 PubMedCrossRef
12.
Freedman DM, Looker AC, Chang SC, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99(21):1594–1602PubMedCrossRef
13.
Garland FC, Garland CF, Gorham ED, Young JF (1990) Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 19(6):614–622PubMedCrossRef
14.
15.
Engel P, Fagherazzi G, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F (2011) Joint effects of dietary vitamin D and sun exposure on breast cancer risk: results from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 20(1):187–198PubMedCrossRef
16.
Medicine IIo (2011) Dietary reference intakes for calcium and vitamin D. The National Academies, Washington
17.
Grant WB (2011) Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level: implications for meta-analyses and setting vitamin D guidelines. Dermatoendocrinology 3(3):199–204. doi:10.​4161/​derm.​3.​3.​15364
18.
Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, wson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84(1):18–28PubMed
19.
Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16(7):713–716PubMedCrossRef
20.
21.
Vieth R (2006) What is the optimal vitamin D status for health? Prog Biophys Mol Biol 92(1):26–32PubMedCrossRef
22.
Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F (2010) Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 19(9):2341–2350PubMedCrossRef
23.
John EM, Schwartz GG, Dreon DM, Koo J (1999) Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971–1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 8(5):399–406
24.
Bolland MJ, Grey A, Gamble GD, Reid IR (2011) Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set. Am J Clin Nutr. doi:10.​3945/​ajcn.​111.​015032
25.
26.
Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J (2010) Serum levels of vitamin D, PTH, calcium and breast cancer risk: a prospective nested case-control study. Int J Cancer 127(9):2159–2168PubMedCrossRef
27.
Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O’Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100(22):1581–1591PubMedCrossRef
28.
Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL, Neugut AI, Santella RM (2009) Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2(6):598–604CrossRef
29.
Colston KW, Lowe LC, Mansi JL, Campbell MJ (2006) Vitamin D status and breast cancer risk. Anticancer Res 26 (4A):2573–2580
30.
Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J (2008) Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer–results of a large case-control study. Carcinogenesis 29(1):93–99PubMedCrossRef
31.
Abbas S, Chang-Claude J, Linseisen J (2009) Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case–control study. Int J Cancer 124(1):250–255PubMedCrossRef
32.
Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW (2005) Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41(8):1164–1169PubMedCrossRef
33.
Fedirko V, Torres-Mejia G, Ortega-Olvera C, Biessy C, Angeles-Llerenas A, Lazcano-Ponce E, Saldana-Quiroz VA, Romieu I (2012) Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case-control study in Mexican women. Cancer Causes Control 23(7):1149–1162. doi:10.​1007/​s10552-012-9984-z PubMedCrossRef
34.
Abbas S, Linseisen J, Chang-Claude J (2007) Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case–control study. Nutr Cancer 59(1):54–61PubMedCrossRef
35.
Knight JA, Lesosky M, Barnett H, Raboud JM, Vieth R (2007) Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16(3):422–429PubMedCrossRef
36.
Grant W (2012) Effect of follow-up time on the relation between prediagnostic serum 25-hydroxyitamin D and all-cause mortality rate. Dermatoendocrinology 4(2):198–202CrossRef
37.
Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF (2000) Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72(3):690–693PubMed
38.
Harvie M, Hooper L, Howell AH (2003) Central obesity and breast cancer risk: a systematic review. Obes Rev 4(3):157–173PubMedCrossRef
39.
Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ (2012) 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat 133(3):1077–1088. doi:10.​1007/​s10549-012-2012-x PubMedCrossRef
40.
Boyages SB, Bilinski K (2012) Seasonal variation in vitamin D persists into spring: Implications for monitoring and replacement therapy. Clin Endocrinol (Oxf.) 77(4):515–523
41.
Daly RM, Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Sikaris KA, Zimmet PZ, Ebeling PR, Shaw JE (2011) Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clin Endocrinol. doi:10.​1111/​j.​1365-2265.​2011.​04320.​x
42.
Pink B (2006) Information paper: an introduction to Socio-Economic Indexes for Areas (SEIFA). Australian Bureau of Statistics, Canberra
43.
Bischoff-Ferrari HA (2008) Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 624:55–71PubMedCrossRef
44.
Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135(2):317–322PubMed
45.
Centre NBaOC (2009) Breast cancer risk factors a review of the evidence. National Breast and Ovarian Cancer Centre, Surry Hills SNW 2010
46.
WHO (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Technical Report Series 894. WHO, Geneva
47.
Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N (2009) Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27(23):3757–3763PubMedCrossRef
48.
Peppone L, Rickles A, Huston A, Sprod L, Hicks D, Mustian K, Skinner K (2011) The association between prognostic demographic and tumor characteristics of breast carcinomas with serum 25-OH vitamin D levels. Cancer Epidemiol Biomarks Prev 20(4):717CrossRef
49.
Colston KW (2008) Vitamin D and breast cancer risk. Best Pract Res Clin Endocrinol Metab 22(4):587–599PubMedCrossRef
50.
Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC (2002) Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 94(17):1301–1311PubMedCrossRef
51.
Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM (2007) Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 167(10):1050–1059PubMedCrossRef
52.
Lagunova Z, Porojnicu AC, Grant WB, Bruland ò, Moan JE (2010) Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? Mol Nutr Food Res 54(8):1127–1133PubMed
53.
54.
55.
56.
Hill A (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300PubMed
57.
Grant WB (2009) How strong is the evidence that solar ultraviolet B and vitamin D reduce the risk of cancer? An examination using Hill’s criteria for causality. Dermatoendocrinology 1(1):17–24CrossRef
58.
Mohr SBGE, Alcaraz JE, Kane CI, Macera CA, Parsons JE, Wingard DL, Garland CF (2012) Does the evidence for an inverse relationship between serum vitamin D status and breast cancer risk satisfy the Hill criteria? Dermatoendocrinology 4(2):152–157CrossRef
Metadata
Title
Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case–control study
Authors
K. Bilinski
J. Boyages
Publication date
01-01-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2381-1

Other articles of this Issue 2/2013

Breast Cancer Research and Treatment 2/2013 Go to the issue

Preclinical Study

Differential expression of immune-related markers in breast cancer by molecular phenotypes

Clinical trial

Effect of HER2 status on distant recurrence in early stage breast cancer

Preclinical Study

Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features

Review

Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis

Epidemiology

Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry

Epidemiology

Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits